Overall, when we analyzed the sensitizing effect of a single treatment of TKIs on P-gp-overexpressing resistant cancer cells, we observed that low doses of crizotinib had higher sensitization effects than those of other TKIs. The gene discussed is PGP; the disease is cancer.